Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ENOCHIAN BIOSCIENCES, INC.

(ENOB)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Enochian Biosciences, Inc. Announces Potential Cure for IV Successfully Completes Pre-Investigational New Drug Stage of U.S. Food and Drug Administration Approval Process

10/19/2021 | 09:05am EST

Enochian Biosciences, Inc. announced that a potential cure for HIV, developed by pioneering research scientist Dr. Serhat Gumrukçu, Director of the Seraph Research Institute, and his team have successfully completed the Pre-Investigational New Drug process for the U.S. Food and Drug Administration Center for Biologics Evaluation and Research. The submission to the FDA was based on promising results achieved by a 54-year-old man living with HIV, who was unable to sustain HIV viral load suppression with antiviral therapy. Once the patient stopped taking ART, and began using the new innovative SRI treatment, his HIV infection blood levels were controlled more effectively for 365 consecutive days.


ę S&P Capital IQ 2021
All news about ENOCHIAN BIOSCIENCES, INC.
11/15ENOCHIAN BIOSCIENCES INC Management's Discussion and Analysis of Financial Condition a..
AQ
11/15Enochian Biosciences, Inc. Reports Earnings Results for the First Quarter Ended Septemb..
CI
10/28Amendment to Annual Report (Form 10-K/A)
PU
10/19Enochian Biosciences, Inc. Announces Potential Cure for IV Successfully Completes Pre-I..
CI
10/18ENOCHIAN BIOSCIENCES ANNOUNCES THE S : The Second Pre-IND in 1 month
PU
10/18ENOCHIAN BIOSCIENCES : Completes FDA Pre-IND for HIV Antiviral Therapy; Shares Down in Pre..
MT
10/18Enochian BioSciences Completes Pre-IND After FDA Comments
DJ
10/18ENOCHIAN BIOSCIENCES ANNOUNCES THE S : The Second Pre-IND in 1 month
AQ
10/18ENOCHIAN BIOSCIENCES ANNOUNCES THE S : The Second Pre-IND in 1 Month
CI
10/15ENOCHIAN BIOSCIENCES : Scientific Advisory Board Member Resigns Due to Conflict with Respo..
PU
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -26,7 M - -
Net cash 2021 13,3 M - -
P/E ratio 2021 -9,71x
Yield 2021 -
Capitalization 573 M 573 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 11
Free-Float 38,9%
Chart ENOCHIAN BIOSCIENCES, INC.
Duration : Period :
Enochian Biosciences, Inc. Technical Analysis Chart | ENOB | US29350E1047 | MarketScreener
Technical analysis trends ENOCHIAN BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Managers and Directors
Mark Richard Dybul Executive Vice Chairman & Chief Executive Officer
Luisa Puche Chief Financial Officer
Rene Sindlev Chairman
Joseph R. Cohen Director-Research & Discovery
Carl Sandler Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ENOCHIAN BIOSCIENCES, INC.272.20%573
GILEAD SCIENCES, INC.20.27%87 895
BIONTECH SE273.85%73 606
REGENERON PHARMACEUTICALS34.17%67 771
WUXI APPTEC CO., LTD.24.40%62 328
VERTEX PHARMACEUTICALS-21.20%47 352